“…The primary endpoint (at least 30 mm improvement of at least 2 among 4 VASs assessing global activity by the patient, dryness, fatigue, and pain) was not met at the study completion (week 24), but only at an earlier time point (week 6). However, several other secondary outcome measures were improved, notably salivary flow and salivary gland ultrasonographic abnormalities, 24 raising the possibility that the predefined primary endpoint was not able to measure a positive effect of the treatment. The TRACTISS trial included 133 patients with pSS: 66 were assigned to receive placebo and 67 to rituximab (1000 mg) at weeks 0, 2, 24, and 26.…”